Comparative Pharmacology
Head-to-head clinical analysis: REGROTON versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGROTON versus RENESE R.
REGROTON vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination